Cut Costs, Not Quality: How excipient vendors can use LOE dates to pitch cost-down excipient substitutions
The Financial Physics of Patent Cliffs The pharmaceutical sector is approaching a revenue precipice. Between 2025 and 2030, an estimated […]
How Abandoned Drug Patents Become Your Competitive Weapon
Every year, pharmaceutical companies abandon tens of thousands of patents and patent applications — quietly, deliberately, and in ways that
How Abandoned Drug Patents Become Your Competitive Weapon Read Post »
When Blockbusters Fall, Business Development Rises: Win the Patent Cliff
The pharmaceutical industry is entering a $400 billion revenue transfer. Between 2025 and 2030, nearly 200 blockbuster drugs will lose
When Blockbusters Fall, Business Development Rises: Win the Patent Cliff Read Post »
Maximizing GLP-1 Market Exclusivity: Leveraging Patent Term Extension (PTE) and NCE Exclusivity to Protect Blockbuster Status
The Metamorphosis of the Global GLP-1 Market: A Strategic Overview The pharmaceutical landscape is currently undergoing a structural transformation of
Algorithms Don’t Own Patents: How to Win the AI Drug Race
The pharmaceutical industry has a new problem it didn’t anticipate when it started pouring billions into artificial intelligence: the machines
Algorithms Don’t Own Patents: How to Win the AI Drug Race Read Post »
Build Your Drug Portfolio’s Moat Before the $400 Billion Patent Cliff Swallows It
The numbers are not abstract. Between 2025 and 2030, branded pharmaceutical products generating roughly $400 billion in annual global revenue
Build Your Drug Portfolio’s Moat Before the $400 Billion Patent Cliff Swallows It Read Post »
Cut Drug R&D Costs by 90%: The 505(b)(2) Playbook the Big Pharma Textbook Ignores
Full drug development — from first synthesis of a new chemical entity to FDA approval — costs, on average, $2.6
Cut Drug R&D Costs by 90%: The 505(b)(2) Playbook the Big Pharma Textbook Ignores Read Post »
Profit from the Patent Cliff: ANDA Filing Trends Hidden Inside the FDA Orange Book
The FDA Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, is the primary trade ledger
Profit from the Patent Cliff: ANDA Filing Trends Hidden Inside the FDA Orange Book Read Post »
Own the Market: How Brand Companies Strategically List Patents in the FDA Orange Book
The Food and Drug Administration (FDA) Orange Book is the primary financial barrier between a blockbuster drug and its generic
Own the Market: How Brand Companies Strategically List Patents in the FDA Orange Book Read Post »
